Abstract Pancreas cancer is an aggressive and fatal disease that will become one of the leading causes of cancer mortality by 2030. An all-out effort is underway to better understand the basic biologic mechanisms of this disease ranging from early… Read More
Abstract Background. Molecular analysis has revealed four subtypes of pancreatic ductal adenocarcinoma (PDAC). One subtype identified for the presence of DNA damage repair deficiency can be targeted therapeutically with the poly (ADP‐ribose) polymerase (PARP) inhibitor olaparib. We performed a single-institution… Read More
Growth Driving Opportunities and Expansion Imaging Endpoints (IE), with offices in Scottsdale, Ariz., and Waltham, Mass., announced today the promotion of Manual Ramirez, RAC to Chief Compliance and Regulatory Affairs Officer. Ramirez has served as Senior Vice President of Compliance… Read More
Imaging Endpoints (IE) is proud to announce the successful completion of a Bioresearch Monitoring (BIMO) inspection by the U.S. Food and Drug Administration (FDA) at its corporate office in Scottsdale, Ariz., June 7, 2018. The inspection concluded with perfect results; no Form… Read More
RRx-001 is an anticancer agent that subjects cancer cells to reactive oxygen/ nitrogen species (ROS/RNS) and acts as an epigenetic modifier. We have used a thiol-bearing MRI contrast agent, Gd-LC7-SH, to investigate the pharmacodynamics of RRx-001 in CHP-100 Ewing’s Sarcoma,… Read More
Purpose: To determine whether deposition characteristics of ferumoxytol (FMX) iron nanoparticles in tumors, identiﬁed by quantitative MRI, may predict tumor lesion response to nanoli-posomal irinotecan (nal-IRI). Experimental Design: Eligible patients with previously trea-ted solid tumors had FMX-MRI scans before and… Read More
Ramanathan R.K., Korn R.L., Chiorean E.G., Liu H. & Von Hoff D.D. “Positron emission tomography (PET) as a predictive measure in patients with metastatic pancreatic cancer and normal CA19-9 levels at baseline.” Ann Oncol., 00: 1–2, (2016). To read more… Read More
11th Annual TOP Conference – Don’t Forget Clinical Trials Imaging Endpoints CMO and Founder, Ronald Korn, MD., PhD. presents “New Imaging Techniques to Aid Creative Clinical Trial Designs.” This talk will cover the role of imaging in oncology clinical trials… Read More
Dr. Ron Korn, founder and Chief Medical Officer of Imaging Endpoints Core Lab will be a featured speaker at the Cancer Treatment Centers of America® (CTCA) Western Regional Medical Center (Western) Annual New Treatments in Oncology (ANTO) conference. This conference focuses on advances in cancer research, new treatments and patient care.
Imaging Endpoints CMO and Founder, Ronald Korn, MD., PhD. presents “Imaging the Immune System in Solid Tumors.”This talk will cover the spectrum of immunotherapy from an imaging perspective along with current trends including novel imaging methodologies and enhanced techniques beyond conventional imaging. The Immuno-Oncology 360° eventdelves into key areas of business, clinical and scientific advancements including the Business Aspects for IO, Differences of Modalities in Immunotherapy, Methodological Advances – Investigating Immunotherapies in the Clinic, Immunotherapy Practice Altering Clinical Advances, Hematologic Malignancies, Emerging Biomarkers and Randomized Phase II Combination Therapy Trials. Visit us and learn how we can provide imaging expertise to help develop your product in translational and Phase I studies and provide core lab services for Phase I, II, III and IV. For more information, email us at email@example.com or call us at 480.314.3070.
February 2, 2016 – February 3, 2016